ActualEyes, Inc.
PrivateLast Round
Series C
Nov 29, 2024
Est. Valuation
$10.47M
Total Funding Raised
$6.81M
Company Overview
ActualEyes, Inc. operates in Healthcare & Life Sciences and is based in Japan. Its latest recorded funding round was a Series B round in June 2022.
ActualEyes, Inc. is a biotechnology company that develops innovative cell therapy and pharmaceutical treatments for corneal endothelial disorders.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery
Business Model
B2B
Customer Profile
Hardware Sales, Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
ActualEyes, Inc. Comparables
Compare ActualEyes, Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Cellusion Inc. | 87% | |
| SYSTANE | 87% | |
| Trefoil Therapeutics | 85% |
For institutional investors. Book with your work email.
ActualEyes, Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Nov 29, 2024 | ||||
| Series B | Jun 30, 2022 | ||||
| Seed | Oct 9, 2019 |
For institutional investors. Book with your work email.
ActualEyes, Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| WHIZ Partners, Inc. | Seed |
| Mitsubishi UFJ Capital | Seed |
| Japan Science and Technology Agency | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Nov 29, 2024
$331K round with D. Western Therapeutics Institute and Senju Pharmaceutical.
- Jun 30, 2022
$2.4M round led by D. Western Therapeutics Institute, Inc.
For institutional investors. Book with your work email.
ActualEyes, Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about ActualEyes, Inc.'s valuation, stock price, and market status.
Is ActualEyes, Inc. a public or private company?
ActualEyes, Inc. is a private company.
What is the current stock price of ActualEyes, Inc.?
ActualEyes, Inc. is a private company, so its shares have no public market price. Caplight tracks ActualEyes, Inc.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is ActualEyes, Inc. worth (valuation)?
ActualEyes, Inc.'s valuation is estimated at $10.5M based on funding round data.
Can I buy ActualEyes, Inc. stock?
ActualEyes, Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was ActualEyes, Inc.'s last funding round?
ActualEyes, Inc.'s most recent funding round was Series C on November 29, 2024.
Who are the main investors in ActualEyes, Inc.?
Key investors in ActualEyes, Inc. include WHIZ Partners, Inc., Mitsubishi UFJ Capital, Japan Science and Technology Agency.
Will ActualEyes, Inc. IPO soon?
No public IPO plans have been announced for ActualEyes, Inc..
How can I track ActualEyes, Inc. secondary market activity?
Caplight tracks bids, offers, and trades in ActualEyes, Inc.'s shares on secondary markets.